Bio-Rad Laboratories Q3 FY25: revenue $653.0M, up 1%; diluted EPS −$12.70

Key figures from this report

These are the numbers Bio-Rad Laboratories reported for Q3 FY25, the quarter ended Sep 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Revenue$653.0M+1% from $649.7M in Q3 FY2410-Q income statement, on EDGAR
2. Net income−$341.9M−152% from $653.2M in Q3 FY2410-Q income statement, on EDGAR
3. Diluted EPS−$12.70−154% from $23.34 in Q3 FY2410-Q income statement, on EDGAR
4. Cash and cash equivalents$395.8M−4% from $410.4M in Q3 FY24Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
5. Cash from operations$120.9M−26% from $163.6M in Q3 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables